Clinical Trial: Transcutaneous Interferential Electrical Stimulation in Individuals with Irritable Bowel Syndrome – A Prospective Double-Blind Randomized StudyÇoban S.a · Akbal E.b · Köklü S.b · Köklü G.d · Ulaşlı M.A.c · Erkeç S.c · Aktaş B.a · Yüksel O.a · Koçak E.b · Erdem H.R.c
aDepartment of Gastroenterology, Diskapi Yildirim Beyazit Education and Research Hospital, Departments of bGastroenterology and cPhysical Medicine and Rehabilitation, Ankara Education and Research Hospital, and dDepartment of Physical Medicine and Rehabilitation, Hacettepe University School of Medicine, Ankara, Turkey
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: The exact etiology of irritable bowel syndrome (IBS) remains unclear. Curative treatment is not available and current treatment modalities are mainly directed against the predominant symptoms. There are a few studies reporting the beneficial effects of transcutaneous electrical stimulation in patients with chronic constipation, gastroparesis, and functional dyspepsia. Aim: To investigate whether transcutaneous electrical stimulation is an effective procedure in IBS patients. Methods: IBS patients were randomly placed in vacuum interferential current (IFC) and placebo groups. Both treatments consisted of 12 sessions administered over 4 weeks. Symptoms due to IBS were documented via questionnaires, including the IBS Global Assessment of Improvement Scale, numeric rating scales, visual analogue scale, and IBS Quality of Life Scale at the beginning of, end of, and 1 month after the treatment. Results: Patients in the therapy (29 cases) and placebo (29 cases) groups were homogeneous with respect to demographic data and gastrointestinal system symptoms. When compared to the beginning scores, severity of abdominal discomfort, bloating, and abdominal distension and rumbling improved significantly in either interference or placebo groups at both the end of treatment and 1 month after treatment. In the IFC group, severity of symptoms continued to decrease significantly at 1 month after treatment when compared to scores at just the end of treatment, whereas in the placebo group severity of these symptoms did not change significantly on numeric severity scales. Also, the visual analogue scale of the first month after treatment continued to decrease significantly when compared to the level at the end of treatment in the IFC group. Total quality score increased significantly in the IFC group. Conclusions: Vacuum IFC therapy can significantly improve symptoms and quality of life in patients with IBS. It may represent a novel treatment modality for drug-refractory IBS patients.
© 2012 S. Karger AG, Basel
- Hungin AP, Whorwell PJ, Tack J, Mearin F: The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003;17:643–650.
Harvey RF, Salih SY, Read AY: Organic and functional disorders in 2,000 gastroenterology outpatients. Lancet 1983;321:632–634.
American College of Gastroenterology Task Force of Irritable Bowel Syndrome: An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104(suppl 1):S1–S35.
- Chase J, Robertson VJ, Southwell B, Hutson J, Gibb S: Pilot study using transcutaneous electrical stimulation (interferential current) to treat chronic treatment-resistant constipation and soiling in children. J Gastroenterol Hepatol 2005;20:1054–1061.
- McCallum RW, Dusing RW, Sarosiek I, Cocjin J, Forster J, Lin Z: Mechanisms of symptomatic improvement after gastric electrical stimulation in gastroparetic patients. Neurogastroenterol Motil 2010;22:161–167, e50–1.
Emmerson C: A preliminary study of the effect of interferential therapy on detrusor instability in patients with multiple sclerosis. Aust J Physiother 1987;33:64–65.
- Clarke MCC, Chase JW, Gibb S, et al: Decreased colonic transit time after transcutaneous interferential electrical stimulation in children with slow transit constipation. J Pediatr Surg 2009;44:408–412.
- Clarke MCC, Chase JW, Gibb S, Hutson JM, Southwell BR: Improvement of quality of life in children with slow constipation after treatment with transcutaneous interferential electrical stimulation. J Pediatr Surg 2009;44:1268–1273.
- Tack J: Gastric motor and sensory function. Curr Opin Gastroenterol 2009;25:557–565.
- Park MI, Camilleri M: Gastroparesis: clinical update. Am J Gastroenterol 2006;101:1129–1139.
Weinkauf JG, Yiannopoulos A, Faul JL: Transcutaneous electrical nerve stimulation for severe gastroparesis after lung transplantation. J Heart Lung Transplant 2005;24:1444.
- Koklu S, Koklu G, Ozguclu E, Kayani GU, Akbal E, Hasçelik Z: Clinical trial: interferential electric stimulation in functional dyspepsia patients – a prospective randomized study. Aliment Pharmacol Ther 2010;31:961–968.
- Koloski NA, Talley NJ, Boyce PM: The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol 2000;95:67–71
- Dalrymple J, Bullock I: Diagnosis and management of irritable bowel syndrome in adults in primary care: summary of NICE guidance. BMJ 2008;336:556–558.
- Lin Z, Forster J, Sarosiek I, McCallum RW: Effect of high-frequency gastric electrical stimulation on gastric myoelectric activity in gastroparetic patients. Neurogastroenterol Motil 2004;16:205–212.
- McCallum R, Lin Z, Wetzel P, Sarosiek I, Forster J: Clinical response to gastric electrical stimulation in patients with postsurgical gastroparesis. Clin Gastroenterol Hepatol 2005;3:49–54.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.